INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Benzeno Sharon reported ADPT

Chief Commercial Ofc Imm Med · Adaptive Biotechnologies Corp · Common Stock

Side
M
Value
$17K
Shares
4,157
Price
$3.99
Executed
Dec 4, 2025
Disclosed
Dec 8, 2025
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Dec 4 executedDec 8, 2025 disclosed

ADPT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

$17K reported value · 1.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ADPT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M$144K
    11.9K sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M$144K
    11.9K sh
    		Oct 29, 2026Oct 29, 2026
    traded Oct 29, 2026
    		+0dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M—
    11.9K sh
    		Oct 28, 2026Oct 29, 2026
    traded Oct 28, 2026
    		+1dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M—
    11.9K sh
    		Oct 29, 2026Oct 29, 2026
    traded Oct 29, 2026
    		+0dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$5,780
    200 sh
    		Oct 28, 2026Oct 29, 2026
    traded Oct 28, 2026
    		+1dSEC FORM 4

    Evidence

    1
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$80K
    3,000 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$332K
    11.7K sh
    		Oct 28, 2026Oct 29, 2026
    traded Oct 28, 2026
    		+1dSEC FORM 4

    Evidence

    4
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$336K
    11.9K sh
    		Oct 29, 2026Oct 29, 2026
    traded Oct 29, 2026
    		+0dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M—
    11.9K sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M$144K
    11.9K sh
    		Oct 28, 2026Oct 29, 2026
    traded Oct 28, 2026
    		+1dSEC FORM 4

    Evidence

    1
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$244K
    8,881 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$43K
    1,700 sh
    		Oct 22, 2026Oct 26, 2026
    traded Oct 22, 2026
    		+4dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M$144K
    11.9K sh
    		Oct 22, 2026Oct 26, 2026
    traded Oct 22, 2026
    		+4dSEC FORM 4

    Evidence

    1
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$110K
    4,500 sh
    		Oct 23, 2026Oct 26, 2026
    traded Oct 23, 2026
    		+3dSEC FORM 4

    Evidence

    1
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$248K
    10.2K sh
    		Oct 22, 2026Oct 26, 2026
    traded Oct 22, 2026
    		+4dSEC FORM 4

    Evidence

    1
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$187K
    7,381 sh
    		Oct 23, 2026Oct 26, 2026
    traded Oct 23, 2026
    		+3dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M—
    11.9K sh
    		Oct 26, 2026Oct 26, 2026
    traded Oct 26, 2026
    		+0dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M—
    11.9K sh
    		Oct 23, 2026Oct 26, 2026
    traded Oct 23, 2026
    		+3dSEC FORM 4

    Evidence

    0
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Option exercise · 10b5-1 plan
    		M—
    11.9K sh
    		Oct 22, 2026Oct 26, 2026
    traded Oct 22, 2026
    		+4dSEC FORM 4

    Evidence

    1
    RJ
    Rubinstein JuliePresident and COO
    ADPTAdaptive Biotechnologies Corp
    Open-market sale · 10b5-1 plan
    		SELL$89K
    3,378 sh
    		Oct 26, 2026Oct 26, 2026
    traded Oct 26, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001780854-25-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 4, 2025
    Published
    Dec 8, 2025
    Ingested by INSIDER
    Nov 5, 04:29 UTC
    Last re-read
    Nov 5, 04:29 UTC

    Extracted facts

    Filer
    Benzeno Sharon
    Role
    Chief Commercial Ofc Imm Med
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Adaptive Biotechnologies Corp
    Ticker
    ADPT
    Shares
    4,157
    Price per share
    $3.99
    Value
    $16,586
    Execution date (reported)
    Dec 4, 2025
    Owned after transaction
    309.4K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 4,157
    • Price: $3.99

    = $16,586

    What this establishes

    Benzeno Sharon filed this Form 4 reporting a option exercise of ADPT on Dec 4, 2025. It became public on Dec 8, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Ofc Imm Med
    Benzeno Sharoncik:0001780854
    Issuer
    Adaptive Biotechnologies Corpcik:0001478320

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.